Pediatrics Region: Nephmadness 2018

Many kidney disorders diagnosed in childhood persist into adulthood and have serious consequences not only on kidney health, but on cardiovascular health as well. Pediatric CKD differs from CKD in adults in that it is predominantly caused by congenital anomalies of the kidney and urinary tract (CAKUT) and glomerulonephritis rather than the more typical adult diseases of diabetes and hypertension. Hypertension screening, diagnosis, and treatment are also more nuanced in children.

Check out the full NephMadness Pediatrics Region here

Target Audience

  • Physicians
  • Read the educational summary for the Pediatrics Region here
  • Make sure you completed a bracket with your predictions of what concepts are the most important or most impactful here
  • Participate in social media (Twitter, Instagram, Facebook, blogs) discussions about these concepts, sharing your opinions of what is the most important or impactful to you in nephrology.  
  • Login or create an account to this site and complete the evaluations and download certificate.

Learning Objectives

After participation in this activity, learners will be able to:

  • Recognize the various roles of both genetics and environment in early renal development
  • Describe the approach for screening and a genetic workup in the evaluation of glomerular diseases in children
  • Recognize the difference between pediatric and adult onset guidelines for hypertension and review various treatment options for the different age groups
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
Course opens: 
Course expires: 

Michelle Rheault, MD
Associate Professor 
University of Minnesota 
Minneapolis, MN 
Disclosure: Research funding (Alport syndrom): Reata, Regulus Therapeutics, Novartis. Research funding (FSGS): Retrophin 

Planning Committee Disclosures

Anna Burgner, MD, MEHP
Assistant Professor 
Vanderbilt Medical Center
Nashville, TN 
Disclosure: Primary Investigator: Bayer (Diabetic Nephropathy); inRegen (Diabetic Nephropath); AstraZeneca (CKD); Fibrogen (Anemia)

Danielle Nathan, MA
Professional Education Director
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).

Kathryn Troy, MPH
Professional Education Coordinator
National Kidney Foundation
New York, NY
Disclosure: Has no financial relationships with commercial interest(s).


It is the policy of the National Kidney Foundation (NKF) to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. Any individual who has control over CME/CE content is required to disclose to learners prior to the activity any relevant financial relationship(s) they may have with commercial interests supporting this activity or whose products or devices are discussed in this activity.  

If, on the basis of information disclosed, a perceived conflict exists, resolution will be achieved based on NKF's Disclosure and Conflict of Interest Policy.


During their presentations, faculty may discuss an unlabeled use or an investigational use not approved for a commercial product. Each faculty member is required to disclose this information to the audience when referring to an unlabeled or investigational use.

The National Kidney Foundation is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.




The National Kidney Foundation designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit™


Please login or register for a PERC account to take this course.

The faculty and National Kidney Foundation (NKF) do not recommend the use of any pharmaceutical, diagnostic test, or device outside of the labeled indications as approved by the FDA. Please refer to the official prescribing information for each product for approved indications, contraindications, and warnings.

Information contained in this NKF educational resource is based upon current data available at the time of publication. Information is intended to help clinicians become aware of new scientific findings and developments.  This NKF educational resource is not intended to set out a preferred standard of care and should not be construed as one. Neither should the information be interpreted as prescribing an exclusive course of management.

Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional making use of information in this NKF educational resource is responsible for interpreting the data as it pertains to clinical decision making in each individual patient.